Medicine and Dentistry
Polycystic Ovary Syndrome
75%
Mifepristone Plus Misoprostol
50%
Endothelial Cell
50%
Glutamine
50%
Water-Electrolyte Imbalance
27%
Cell Adhesion Molecule
27%
Adenomyosis
25%
Cell Adhesion Molecule 1
25%
Adenocarcinoma
25%
Gonadotropin Release
25%
Pessary
25%
Stress Incontinence
25%
COVID-19
25%
Molar Pregnancy
25%
Neutrophil
25%
Leukocyte
25%
Randomized Controlled Trial
25%
Nodular Melanoma
25%
Meta-Analysis
25%
Restylane
25%
Impaired Glucose Tolerance
25%
Interstitial Cystitis
25%
Scopolamine
25%
Visual Analog Scale
25%
Pre-Eclampsia
22%
Histopathology
18%
Severe Acute Respiratory Syndrome Coronavirus 2
18%
Human Umbilical Vein Endothelial Cell
18%
Diagnosis
17%
Endometrium
15%
Surgeon
15%
Bleeding
14%
Body Mass Index
14%
Metabolic Syndrome
12%
Dilation and Curettage
12%
Vacuum Aspiration
12%
Uterine Prolapse
12%
Treatment Response
12%
Bladder Capacity
12%
Intracytoplasmic Sperm Injection
12%
Cystalgia
12%
Spotting
11%
Infection
10%
Uterine Myomectomy
10%
Urologist
10%
Premenopause
10%
Malignant Transformation
10%
Disease
10%
Retroperitoneal Lymph Node Dissection
10%
Apgar Score
9%
Nursing and Health Professions
Ovary Polycystic Disease
100%
Metabolic Disorder
27%
Gonadotropin
25%
Scopolamine
25%
Impaired Glucose Tolerance
25%
Stress Incontinence
25%
Syndrome
25%
Meta Analysis
25%
Suburethral Sling
20%
Body Mass
15%
Confidence Interval
15%
Metabolic Syndrome X
13%
Hyperandrogenism
11%
Diagnosis
11%
Insulin Resistance
10%
Pubovaginal Sling
10%
Gynecologist
10%
Hospital Accreditation
10%
Urologist
10%
Hospital
10%
Anovulation
8%
Androgen
7%
Prevalence
7%
Adverse Event
6%
Triacylglycerol
5%
Receiver Operating Characteristic
5%
National Health Insurance
5%
Health Care Personnel
5%
Pharmacology, Toxicology and Pharmaceutical Science
Arginine
25%
Mifepristone Plus Misoprostol
25%
Randomized Controlled Trial
25%
Ovary Polycystic Disease
25%
Syndrome
25%
Hydatidiform Mole
25%
Angiogenic Protein
25%
Scopolamine
25%
Bleeding
8%
Trophoblastic Tumor
8%
Chorionic Gonadotropin Beta Subunit
8%
Nitric Oxide
6%
Adverse Event
6%